Observational studyAIDS (London, England)2025
Factors influencing antiretroviral therapy switching in people with virologically suppressed HIV-1: a cross-sectional multicenter study in France.
Observational study in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Treatment durability, satisfaction and quality of life in virologically suppressed HIV-1 people switching to doravirine: Results from the French study DoraVIH.HIV medicine · 2026Article
- Antiretroviral therapy switch among Medicare beneficiaries with HIV.Journal of managed care & specialty pharmacy · 2026Article
- Real-World Persistence After Starting Bictegravir- or Dolutegravir-Based Regimens Among Adults Aged ≥50 Years with HIV in the United States.Drugs & aging · 2026Article
- Treatment Persistence and Switch Among Medicare-Insured People with HIV and Gaps in Care.Infectious diseases and therapy · 2026Article
- Antiretroviral Treatment Switch Among Treatment-Experienced People with HIV.Journal of health economics and outcomes research · 2026Article
- Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy.The Journal of antimicrobial chemotherapy · 2025Article
- Antiretroviral Therapy-Associated Weight Gain in Mexico, a Country Prone to Comorbidities.International journal of health policy and management · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn France, over 90% of people with HIV-1 (PWH) achieve virological suppression with effective combination of antiretroviral therapies (ART), but limited data exist on the motivation for switching ART.
objectiveTo describe the reasons and determinants for switching ART, with a particular focus on doravirine-based regimens, in routine clinical practice in France.
designThis analysis of cross-sectional baseline data is part of the DoraVIH study, a French, multicenter (15 sites), two-step observational cohort study that includes prospective follow-up for a subset of participants.
methodsEligible participants were PWH under ART regimen, virologically suppressed for at least 6 months, doravirine-naive and switching ART regimen. Sociodemographic and clinical data, ART history and reasons for switching ART were assessed at baseline.
resultsInclusions occurred between 13 December 2021 and 21 September 2022. Of the 291 PWH included, whose data were analyzed, 143 switched to doravirine-based regimen (DOR PWH) and 148 to another combined regimen (non-DOR PWH). Mean age was 51.6 years, and 206 participants (70.8%) were men. At baseline, 35 (25.0%) DOR PWH and 15 (10.6%) non-DOR PWH had BMI at least 30 kg/m 2 ( P = 0.007). The most common reasons for switching were treatment simplification, tolerability and drug-drug interactions, accounting for 79.7% of all reasons. Among the 68 participants with prior tolerability issues, 47 (69.1%) switched to doravirine-based regimen.
conclusionPrimary reasons for switch were treatment simplification and tolerability. Participants with obesity were more likely to switch to doravirine, reflecting physicians' favorable perception of doravirine potential benefits, particularly in managing weight gain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.